The NeurologyLive Expert Authors page highlights all the content published on our site that was authored by subject matter experts, including clinicians, neurologists, neurology specialists, advanced practice providers, and more.
Are you a subject matter expert who's interested in submitting to NeurologyLive? Contact our editorial director, Matt Hoffman, by email: mhoffman@mjhlifesciences.com.
Caregiving Youth: A Call to Action for Improved Support
January 27th 2024A systematic approach to understanding the needs of the caregiving youth—a growing and less-studied population of caregivers—is needed to better tailor interventions, provide support, and improve care to patients and their families.
Medical Gaslighting: Multiple Sclerosis’ Dirty Little Secret?
The effect of gaslighting on patients can result in serious harms, and although it is potentially common in the MS care continuum, whether it is deliberate or an institutional problem, it must be called out by providers.
Challenges of Shared Decision-Making in the Management of Multiple Sclerosis
August 30th 2023Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.
Digital Health Tool Offers Innovative Quantitative Fall Assessment Solution for Older Adults
Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.
Promising Disease-Modifying Therapies in Parkinson Disease
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Therapeutic Potential of IGF-1 and MECP2 in Rett Syndrome
April 16th 2023Research that is already underway will be necessary to confirm the safety and efficacy of this class of Rett syndrome therapies, and targeting IGF-1 may be a possibility for treating additional neurological disorders beyond Rett.
Therapeutics Aim at Modifying Alzheimer Disease
April 16th 2023Disease-modifying agents will require early detection, including comprehensive evaluation of disease severity and alternative or confounding diagnoses. When the long-awaited moment arrives, when disease-modifying therapies finally are available for ADRDs…will we be ready?
An Overview of Therapeutic Options for Amyotrophic Lateral Sclerosis
March 4th 2023With an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.